Alvin Lang
April 22, 2025 06:43
Brainstorm Therapeutics aims to develop drug discovery of brain diseases using AI and Ogannoits to reduce clinical trial failures and accelerate treatment development.
In a breakthrough approach to fighting neurological disorders, Brainstorming drugs, a start -up -based start -up -based start -up, are using artificial intelligence (AI) along with Ogaid Technology to quickly discover the treatment of brain diseases. According to NVIDIA’s blog, this innovative method is to overcome the high failure rate of traditional drug candidates in clinical trials.
AI and Ogannoid: New border
Brainstorm Therapeutics uses a hybrid process that is known as a ‘laboratory’ that integrates AI -based calculation drug discovery with laboratory experiments using Organoids. This Oganide is a small three -dimensional brain cell cluster derived from patient stem cells. This approach often allows more accurate predictions of human efficacy compared to the existing preclinical models that often do not accurately reflect human neurological biology.
Robert Fremeau, the founder and CEO of Brainstorm, emphasized the potential to solve a complex disease network by combining the Organoid Disease model with AI. The company’s goal is to significantly reduce the failure rate of more than 93%of drug candidates and identify treatments that apply to various diseases.
Clinical trial on a plate
Brainstorming uses the AI model to create a gene map of brain disease to identify promising drug targets and biomarkers. Oganid can screen thousands of drug molecules directly in human brain cells. This ability provides ‘clinical trial in a plate’ to accelerate the discovery process by allowing the initial stage test of potential therapy.
New companies are currently focusing on Parkinson’s diseases, and uses Ogano for patients with GBA1 gene mutant, a known risk factor. By mapping and analyzing the biological effects of genetic variants, brainstorming aims to develop a treatment that can slow or reverse the progression of the disease.
Drug discovery acceleration
Brainstorm’s platforms, driven by NVIDIA GPUS and Bionemo frameworks, simulate the therapeutic effect by reflecting human brain biology. This feature allows you to get a quick and cost efficient narrow of the treatment options before going through a human exam. This technology has discovered a new application for existing drugs, such as Done Pegil for RETT syndrome, and has been removed by the US FDA.
The company plans to develop a multimodal AI model that integrates various data types, including cell sequencing and EEG scan to improve drug discovery and precision medicine. Their next project emphasizes the possibility of deformation of AI in rare disease studies by screening drugs for CDKL5 deficiency disorders, including collaboration with Cure5 Foundation.
Brainstorm’s work shows how AI and Organoid technology rapidly accelerates the innovation of drug discovery, reducing costs and timelines for decades to months, to show more efficient and effective treatment for neurological disorders.
Image Source: Shutter Stock